{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:17:01Z","timestamp":1767849421232,"version":"3.49.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100009754","name":"Galderma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009754","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s13555-024-01215-y","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T03:36:50Z","timestamp":1718941010000},"page":"1739-1753","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The \u201cPersonalising Actinic Keratosis Treatment for Immunocompromised Patients\u201d (IM-PAKT) Project: An Expert Panel Opinion"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8452-0737","authenticated-orcid":false,"given":"Rolf-Markus","family":"Szeimies","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claas","family":"Ulrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Ferr\u00e1ndiz-Pulido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunther F. L.","family":"Hofbauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John Thomas","family":"Lear","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celeste","family":"Lebb\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Piaserico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merete","family":"H\u00e6dersdal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,21]]},"reference":[{"key":"1215_CR1","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3390\/medicina55040092","volume":"55","author":"A Balcere","year":"2019","unstructured":"Balcere A, Kupfere MR, \u010c\u0113ma I, Kr\u016bmi\u0146a A. Prevalence, discontinuation rate, and risk factors for severe local site reactions with topical field treatment options for actinic keratosis of the face and scalp. Medicina (Kaunas). 2019;55:92.","journal-title":"Medicina (Kaunas)"},{"key":"1215_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/jdv.14091","volume":"31","author":"R Cerio","year":"2017","unstructured":"Cerio R. The importance of patient-centred care to overcome barriers in the management of actinic keratosis. J Eur Acad Dermatol Venereol. 2017;31:17\u201320.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1215_CR3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/bjd.15107","volume":"176","author":"D de Berker","year":"2017","unstructured":"de Berker D, McGregor JM, Mohd Mustapa MF, Exton LS, Hughes BR. British Association of Dermatologists\u2019 guidelines for the care of patients with actinic keratosis. Br J Dermatol. 2017;176:20\u201343.","journal-title":"Br J Dermatol"},{"key":"1215_CR4","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1111\/bjd.20974","volume":"187","author":"ZU Hasan","year":"2022","unstructured":"Hasan ZU, Ahmed I, Matin RN, et\u00a0al. Topical treatment of actinic keratoses in organ transplant recipients: A feasibility study for SPOT (Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments). Br J Dermatol. 2022;187:324\u201337.","journal-title":"Br J Dermatol"},{"key":"1215_CR5","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1172\/JCI57415","volume":"122","author":"V Ratushny","year":"2012","unstructured":"Ratushny V, Gober MD, Hick R, Ridky TW, Seykora JT. From keratinocyte to cancer: The pathogenesis and modelling of cutaneous squamous cell carcinoma. J Clin Invest. 2012;122:464\u201372.","journal-title":"J Clin Invest"},{"key":"1215_CR6","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1002\/pds.5430","volume":"31","author":"KJ Supapannachart","year":"2022","unstructured":"Supapannachart KJ, Kwon CW, Tushe S, Guest JL, Chen SC, Yeung H. Validation of actinic keratosis diagnosis and treatment codes among veterans living with HIV. Pharmacoepidemiol Drug Saf. 2022;31:998\u20131002.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1215_CR7","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1111\/bjd.15884","volume":"178","author":"K Togsverd-Bo","year":"2018","unstructured":"Togsverd-Bo K, Halldin C, Sandberg C, et\u00a0al. Photodynamic therapy is more effective than imiquimod for actinic keratosis in organ transplant recipients: A randomized intraindividual controlled trial. Br J Dermatol. 2018;178:903\u20139.","journal-title":"Br J Dermatol"},{"key":"1215_CR8","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.jaad.2022.06.014","volume":"88","author":"MR Lindberg","year":"2023","unstructured":"Lindberg MR, Kent RA, DeSimone JA. Quarterly photodynamic therapy for prevention of nonmelanoma skin cancer in organ transplant recipients: an observational prospective cohort study. J Am Acad Dermatol. 2023;88:463\u20135.","journal-title":"J Am Acad Dermatol"},{"key":"1215_CR9","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/jdv.15852","volume":"34","author":"YCC Liew","year":"2020","unstructured":"Liew YCC, De Souza NNA, Sultana RG, Oh CC. Photodynamic therapy for the prevention and treatment of actinic keratosis\/squamous cell carcinoma in solid organ transplant recipients: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2020;34:251\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1215_CR10","doi-asserted-by":"publisher","first-page":"e209","DOI":"10.1016\/j.jaad.2021.02.082","volume":"85","author":"DB Eisen","year":"2021","unstructured":"Eisen DB, Asgari MM, Bennett DD, et\u00a0al. Guidelines of care for the management of actinic keratosis. J Am Acad Dermatol. 2021;85:e209\u201333.","journal-title":"J Am Acad Dermatol"},{"key":"1215_CR11","first-page":"275","volume":"18","author":"MV Heppt","year":"2020","unstructured":"Heppt MV, Leiter U, Steeb T, et\u00a0al. S3 guidelines for actinic keratosis and cutaneous squamous cell carcinoma \u2013 short version, part 1: Diagnosis, interventions for actinic keratoses, care structures and quality-of-care indicators. J Dtsch Dermatol Ges. 2020;18:275\u201394.","journal-title":"J Dtsch Dermatol Ges"},{"key":"1215_CR12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/j.1468-3083.2011.04356.x","volume":"27","author":"N Basset-Seguin","year":"2013","unstructured":"Basset-Seguin N, Baumann Conzett K, Gerritsen MJP, et\u00a0al. Photodynamic therapy for actinic keratosis in organ transplant patients. J Eur Acad Dermatol Venereol. 2013;27:57\u201366.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1215_CR13","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12955-015-0295-4","volume":"13","author":"GR Tennvall","year":"2015","unstructured":"Tennvall GR, Norlin JM, Malmberg I, Erlendsson AM, H\u00e6dersdal M. Health related quality of life in patients with actinic keratosis\u2014an observational study of patients treated in dermatology specialist care in Denmark. Health Qual Life Outcomes. 2015;13:111.","journal-title":"Health Qual Life Outcomes"},{"key":"1215_CR14","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/bjd.15709","volume":"177","author":"P Abbott","year":"2017","unstructured":"Abbott P. Patient-centred health care for people with chronic skin conditions. Br J Dermatol. 2017;177:329\u201330.","journal-title":"Br J Dermatol"},{"key":"1215_CR15","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1111\/jdv.15913","volume":"33","author":"L Eicher","year":"2019","unstructured":"Eicher L, Knop M, Aszodi N, Senner S, French LE, Wollenberg A. A systematic review of factors influencing treatment adherence in chronic inflammatory skin disease \u2013 strategies for optimizing treatment outcome. J Eur Acad Dermatol Venereol. 2019;33:2253\u201363.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1215_CR16","doi-asserted-by":"publisher","first-page":"adv6229","DOI":"10.2340\/actadv.v103.6229","volume":"103","author":"C Morton","year":"2023","unstructured":"Morton C, Baharlou S, Basset-Sequin N, et\u00a0al. Expert recommendations on facilitating personalized approaches to long-term management of actinic keratosis: The Personalizing Actinic Keratosis Treatment (PAKT) project. Acta Derm Venereol. 2023;103:adv6229.","journal-title":"Acta Derm Venereol"},{"key":"1215_CR17","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1177\/1203475415583414","volume":"19","author":"Y Poulin","year":"2015","unstructured":"Poulin Y, Lynde CW, Barber K, et\u00a0al. Non-melanoma skin cancer in Canada chapter 3: Management of actinic keratoses. J Cutan Med Surg. 2015;19:227\u201338.","journal-title":"J Cutan Med Surg"},{"key":"1215_CR18","first-page":"e1","volume":"29","author":"RN Werner","year":"2015","unstructured":"Werner RN, Jacobs A, Rosumeck S, Erdmann R, Sporbeck B, Nast A. Methods and results report\u2014evidence and consensus-based (S3) guidelines for the treatment of actinic keratosis\u2014International League of Dermatological Societies in cooperation with the European Dermatology Forum. J Eur Acad Dermatol Venereol. 2015;29:e1\u201366.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1215_CR19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ejca.2020.01.008","volume":"128","author":"AJ Stratigos","year":"2020","unstructured":"Stratigos AJ, Garbe C, Dessinioti C, et\u00a0al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment Eur J Cancer. 2020;128:83\u2013102.","journal-title":"Treatment Eur J Cancer"},{"key":"1215_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcskn.2023.100004","volume":"1","author":"U Leiter","year":"2023","unstructured":"Leiter U, Heppt MW, Steeb T, et\u00a0al. German S3 guideline \u201cactinic keratosis and cutaneous squamous cell carcinoma\u201d \u2013 long version of the update 2023. EJC Skin Cancer. 2023;1: 100004.","journal-title":"EJC Skin Cancer"},{"key":"1215_CR21","doi-asserted-by":"publisher","first-page":"707","DOI":"10.2217\/ahe.11.56","volume":"7","author":"AD Foster","year":"2011","unstructured":"Foster AD, Sivarapatna A, Gress RE. The aging immune system and its relationship with cancer. Aging Health. 2011;7:707\u201318.","journal-title":"Aging Health"},{"key":"1215_CR22","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.3389\/fimmu.2017.01960","volume":"8","author":"T Fulop","year":"2018","unstructured":"Fulop T, Larbi A, Dupuis G, et\u00a0al. Immunosenescence and Inflamm-Aging As Two Sides of the Same Coin: Friends or Foes? Front Immunol. 2018;8:1960.","journal-title":"Front Immunol"},{"key":"1215_CR23","doi-asserted-by":"publisher","first-page":"179","DOI":"10.2147\/CCID.S121323","volume":"10","author":"R Khanna","year":"2017","unstructured":"Khanna R, Bakshi A, Amir Y, Goldenberg G. Patient satisfaction and reported outcomes on the management of actinic keratosis. Clin Cosmet Investig Dermatol. 2017;10:179\u201384.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"1215_CR24","unstructured":"Jinna S, Khandhar PB. Hydroxyurea toxicity. StatPearls. Treasure Island (FL): StatPearls Publishing 2024. Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK537209\/. accessed 17 Mar 2024."},{"key":"1215_CR25","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1136\/ard-2023-224049","volume":"82","author":"MD Russell","year":"2023","unstructured":"Russell MD, Stovin C, Alveyn E, et\u00a0al. JAK inhibitors and the risk of malignancy: A meta-analysis across disease indications. Ann Rheum Dis. 2023;82:1059\u201367.","journal-title":"Ann Rheum Dis"},{"key":"1215_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/jdv.19636","volume":"38","author":"G Pellacani","year":"2024","unstructured":"Pellacani G, Schlesinger T, Bhatia N, et\u00a0al. Efficacy and safety of tirbanibulin 1% ointment in actinic keratoses: Data from two phase-III trials and the real-life clinical practice presented at the European Academy of Dermatology and Venereology Congress 2022. J Eur Acad Dermatol Venereol. 2024;38:3\u201315.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1215_CR27","first-page":"39","volume":"3","author":"JL Cohen","year":"2010","unstructured":"Cohen JL. Actinic keratosis treatment as a key component of preventive strategies for nonmelanoma skin cancer. J Clin Aesthet Dermatol. 2010;3:39\u201344.","journal-title":"J Clin Aesthet Dermatol"},{"key":"1215_CR28","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1093\/bjd\/ljad116","volume":"189","author":"L Griffin","year":"2023","unstructured":"Griffin L, O\u2019Reilly P, Murphy M, et\u00a0al. Photoprotection and skin cancer education: the experiences of renal transplant recipients, a qualitative study\u2014why the \u2018personal touch\u2019 is important. Br J Dermatol. 2023;189:145\u20137.","journal-title":"Br J Dermatol"},{"key":"1215_CR29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/TP.0000000000001447","volume":"101","author":"JW De Fijter","year":"2017","unstructured":"De Fijter JW. Cancer and mTOR inhibitors in transplant recipients. Transplantation. 2017;101:45\u201355.","journal-title":"Transplantation"},{"key":"1215_CR30","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1097\/01.TP.0000184006.43152.8D","volume":"80","author":"HM Kauffman","year":"2005","unstructured":"Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation. 2005;80:883\u20139.","journal-title":"Transplantation"},{"key":"1215_CR31","doi-asserted-by":"publisher","DOI":"10.1097\/TXD.0000000000000579","volume":"2","author":"H Tedesco-Silva","year":"2016","unstructured":"Tedesco-Silva H, Peddi VR, Sanchez-Fructuoso A, et\u00a0al. Open-label, randomized study of transition from tacrolimus to sirolimus immunosuppression in renal allograft recipients. Transplant Direct. 2016;2: e69.","journal-title":"Transplant Direct"},{"key":"1215_CR32","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1111\/j.1600-6143.2011.03573.x","volume":"11","author":"SM Flechner","year":"2011","unstructured":"Flechner SM, Glyda M, Cockfield S, et\u00a0al. The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am J Transplant. 2011;11:1633\u201344.","journal-title":"Am J Transplant"},{"key":"1215_CR33","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s13671-019-00265-2","volume":"8","author":"A Huang","year":"2019","unstructured":"Huang A, Nguyen JK, Austin E, Mamalis A, Jagdeo J. Updated on treatment approaches for cutaneous field cancerization. Curr Dermatol Rep. 2019;8:122\u201332.","journal-title":"Curr Dermatol Rep"},{"key":"1215_CR34","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/ajt.13978","volume":"17","author":"SA Acuna","year":"2017","unstructured":"Acuna SA, Huang JW, Scott AL, et\u00a0al. Cancer screening recommendations for solid organ transplant recipients: A systematic review of clinical practice guidelines. Am J Transplant. 2017;17:103\u201314.","journal-title":"Am J Transplant"},{"key":"1215_CR35","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1001\/jamadermatol.2022.4820","volume":"159","author":"\u00c1 G\u00f3mez-Tom\u00e1s","year":"2023","unstructured":"G\u00f3mez-Tom\u00e1s \u00c1, Bouwes Bavinck JN, Genders R, et\u00a0al. External validation of the Skin and UV Neoplasia Transplant Risk Assessment Calculator (SUNTRAC) in a large European solid organ transplant recipient cohort. JAMA Dermatol. 2023;159:29\u201336.","journal-title":"JAMA Dermatol"},{"key":"1215_CR36","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1111\/tri.13493","volume":"32","author":"A Jambusaria-Pahlajani","year":"2019","unstructured":"Jambusaria-Pahlajani A, Crow LD, Lowenstein S, et\u00a0al. Predicting skin cancer in organ transplant recipients: development of the SUNTRAC screening tool using data from a multicenter cohort study. Transpl Int. 2019;32:1259\u201367.","journal-title":"Transpl Int"},{"key":"1215_CR37","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/j.1365-2133.2009.09453.x","volume":"161","author":"C Ulrich","year":"2009","unstructured":"Ulrich C, J\u00fcrgensen JS, Degen A, et\u00a0al. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol. 2009;161:78\u201384.","journal-title":"Br J Dermatol"},{"key":"1215_CR38","doi-asserted-by":"publisher","first-page":"12622","DOI":"10.3390\/ijms232012622","volume":"23","author":"B Ramchatesingh","year":"2022","unstructured":"Ramchatesingh B, Mart\u00ednez Villarreal A, Arcuri D, et\u00a0al. The use of retinoids for the prevention and treatment of skin cancers: An updated review. Int J Mol Sci. 2022;23:12622.","journal-title":"Int J Mol Sci"},{"key":"1215_CR39","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/j.1600-6143.2011.03751.x","volume":"12","author":"GFL Hofbauer","year":"2012","unstructured":"Hofbauer GFL, Attard NR, Harwood CA, et\u00a0al. Reversal of UVA skin photosensitivity and DNA damage in kidney transplant recipients by replacing azathioprine. Am J Transplant. 2012;12:218\u201325.","journal-title":"Am J Transplant"},{"key":"1215_CR40","doi-asserted-by":"publisher","first-page":"e946","DOI":"10.1111\/jdv.18374","volume":"36","author":"K Togsverd-Bo","year":"2022","unstructured":"Togsverd-Bo K, Sandberg C, Helsing P, et\u00a0al. Cyclic photodynamic therapy delays first onset of actinic keratoses in renal transplant recipients: A 5-year randomized controlled trial with 12-month follow-up. J Eur Acad Dermatol Venereol. 2022;36:e946\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1215_CR41","unstructured":"Danske Multidisciplin\u00e6re Cancer Grupper. Non-melanom hudcancer hos organtransplanterede \u2013 screening, forebyggelse, behandling og opf\u00f8lgning. 2022. Available at: https:\/\/www.dmcg.dk\/Kliniske-retningslinjer\/kliniske-retningslinjer-opdelt-paa-dmcg\/non-melanom\/non-melanom-hudcancer-hos-organtransplanterede--screening-forebyggelse-behandling-og-opfolgning\/. Accessed 17 Jan 2024."},{"key":"1215_CR42","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1093\/ndt\/gfl762","volume":"22","author":"C Ulrich","year":"2007","unstructured":"Ulrich C, Stockfleth E. Azathioprine, UV light, and skin cancer in organ transplant patients\u2014do we have an answer? Nephrol Dial Transplant. 2007;22:1027\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"1215_CR43","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1126\/science.1114233","volume":"309","author":"P O\u2019Donovan","year":"2005","unstructured":"O\u2019Donovan P, Perrett CM, Zhang X, et\u00a0al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science. 2005;309:1871\u20134.","journal-title":"Science"},{"key":"1215_CR44","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1001\/jamadermatol.2013.6249","volume":"150","author":"NF Velez","year":"2014","unstructured":"Velez NF, Karia PS, Vartanov AR, Davids MS, Brown JR, Schmults CD. Association of advanced leukemic stage and skin cancer tumor stage with poor skin cancer outcomes in patients with chronic lymphocytic leukemia. JAMA Dermatol. 2014;150:280\u20137.","journal-title":"JAMA Dermatol"},{"key":"1215_CR45","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/jdv.17405","volume":"36","author":"P Jansen","year":"2022","unstructured":"Jansen P, Lodde GC, Wetter A, et\u00a0al. Checkpoint immunotherapy of cutaneous squamous cell carcinoma in patients suffering from chronic lymphocytic leukaemia: Divergent outcomes in two men treated with PD-1 inhibitors. J Eur Acad Dermatol Venereol. 2022;36:41\u20134.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1215_CR46","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000897","volume":"8","author":"U Leiter","year":"2020","unstructured":"Leiter U, Loquai C, Reinhardt L, et\u00a0al. Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients. J Immunother Cancer. 2020;8: e000897.","journal-title":"J Immunother Cancer"},{"key":"1215_CR47","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1529-8019.2005.05008.x","volume":"18","author":"BT Kovach","year":"2005","unstructured":"Kovach BT, Stasko T. Use of topical immunomodulators in organ transplant recipients. Dermatol Ther. 2005;18:19\u201327.","journal-title":"Dermatol Ther"},{"key":"1215_CR48","first-page":"456","volume":"141","author":"CA Harwood","year":"2015","unstructured":"Harwood CA, Leedham-Green M, Leigh IM, Proby CM. Low-dose retinoids in the prevention of cutaneous squamous cell carcinomas in organ transplant recipients: A 16-year retrospective study. Arch Dermatol. 2015;141:456\u201365.","journal-title":"Arch Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01215-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01215-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01215-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T18:05:18Z","timestamp":1721498718000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01215-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,21]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["1215"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01215-y","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,21]]},"assertion":[{"value":"18 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Rolf Markus Szeimies has received grants from Almirall, Biofrontera, Dr. Wolff-Group, Galderma, Leo Pharma, Novartis, and Photonamic for clinical studies, has received consulting fees and speaker honoraria from Abbvie, Almirall, Eli Lilly, Galderma, Janssen, and Leo Pharma, and is Vice-President of the EURO-PDT Society. Claas Ulrich has received study grants and\/or has served as speaker and advisor for AlphaTau, Almirall, Beiersdorf, BMS, Galderma, GME, Hans Karrer AG, Novartis, Philogen, Pierre Fabre, Regeneron, Sanofi, Sun Pharma. Carla Ferr\u00e1ndiz-Pulido declares to have participated in advisory boards and\/or received honoraria from Almirall, Pierre Fabre, Sanofi, and Sun Pharma. Gunther Hofbauer has received research support from the Swiss National Fund, has acted as a speaker for AbbVie, Galderma Spirig, LEO Pharma, L\u2019Or\u00e9al, Louis Widmer, MEDA, Merck, Novartis, Permamed, Pfizer, Pierre Fabre, Sanofi Genzyme, and acted as a consultant for AbbVie, Almirall, Biofrontera\/Louis Widmer, Galderma Spirig, Hoffmann-La Roche, LEO Pharma, MEDA, Novartis, Sanofi Genzyme. John Thomas Lear has acted as an advisor and received honoraria from Almirall, Galderma, and Leo Pharma. Celeste Lebb\u00e9 has served as a consultant for Bristol Myers Squibb, Galderma, Immunocore, MSD, Novartis, and Pierre Fabre. Stefano Piaserico has no conflicts of interest relating to the publication of this manuscript. Merete H\u00e6dersdal has received research grants from or acted as a consultant for Galderma, Leo Pharma, L\u2019Or\u00e9al\/La Roche-Posay, Lutronic, Procter & Gamble, and Venus Concept, has acted as a lecturer for Galderma, and has received equipment from Cherry Imaging, Cynosure, GME Medical, Lutronic, MiraDry, and Venus Concept.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Information presented in this article is based on previously conducted studies and does not contain any data from new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}